Skip to main content

Coronavirus (COVID-19): Latest Updates | Visitation PoliciesVisitation PoliciesVisitation PoliciesVisitation PoliciesVisitation Policies | COVID-19 Testing | Vaccine InformationVaccine InformationVaccine Information

Explore URMC
menu

Brea C. Lipe, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 276-2596

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Locations

James P. Wilmot Cancer Center
601 Elmwood Ave
Rochester, NY 14642

Faculty Appointments

Patient Care Setting

Cancer

Biography

I am the clinical director of Wilmot's multiple myeloma program, and in the laboratory and in the clinic, I am focused on improving the care of patients with multiple myeloma and other plasma cell dyscrasias. Treatment options and our understanding of multiple myeloma have changed dramatically in the last 10 years. The rapid pace of change, intrinsic disease complexity, and the ability to impact patient lives still leaves me amazed and humbled every day.

I believe that it's important to know my patients as individuals to understand the situational circumstance and personality that drives their treatment goals. Multiple myeloma is a lifelong journey and a strong partnership with my patients is essential to achieving the best quality of care. I have a strong interest in clinical research and like to offer my patients a variety of clinical trial options and treatments based on the most recent data. I have a dedicated support team, so that we can offer patients a team with real myeloma-specific expertise.

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Outside of work, I love to grow things -- flowers, vegetables, orchids, animals, children. I have gotten some of my best gardening tips from my patients.

Conditions I treat:

- Multiple myeloma
- Other plasma cell disorders

Research

In my research laboratory, I am particularly interested in understanding the mechanisms that allow multiple myeloma to develop. I have created a system that lets us mimic in a laboratory, the growth of cancer cells that become multiple myeloma. By studying disease progression, my ultimate goal is to develop therapies to prevent multiple myeloma.

Credentials

Education

2005
MD | Albany Medical Center Hospital

Post-doctoral Training & Residency

07/01/2008 - 06/30/2011
Fellowship in Hematology & Oncology at Dartmouth-Hitchcock Medical Center

07/01/2006 - 06/30/2008
Residency in Internal Medicine at Dartmouth-Hitchcock Medical Center

07/01/2005 - 06/30/2006
Internship in Internal Medicine at Dartmouth-Hitchcock Medical Center

VIEW ALL expand_more

Awards

2017 - Present
Leadership Academy
Sponsor: Southwest Oncology Group (SWOG)

2011
Department of Internal Medicine OSARM Faculty Incubator Scholar

2011
Clinical Research Training Institute Clinical Scholar for ASH

2009
Award for Excellence in Teaching

2007
Award for Excellence in Teaching

2001 - 2005
Frank C. Knievel Scholarship Award

1996 - 2001
First Generation Diversity Scholarship

VIEW ALL expand_more

Clinical Trials

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Lead Researcher: Brea C Lipe

This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy. This is a study based on adaptive design for decision making of treatment options. Duration of therapy (daratumumab cycles) will depend on individual approach, response, evidence of disease progression and tolerance.

View Study Details

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients With Relapsed/Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

View Study Details

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).

View Study Details

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Lead Researcher: Brea C Lipe

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

View Study Details

A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma

Lead Researcher: Brea C Lipe

This trial will study SEA-BCMA to find out whether it is an effective treatment for multiple myeloma (MM) and what side effects (unwanted effects) may occur. The study will have several parts. In Parts A and B, participants get SEA-BCMA by itself. This part of the study will find out how much SEA-BCMA should be given for treatment and how often. It will also find out how safe the treatment is and how well it works. In Part C of the study, participants will get SEA-BCMA and dexamethasone. In Part D, participants will get SEA-BCMA, dexamethasone, and pomalidomide. Dexamethasone and pomalidomide are both drugs that can be used to treat multiple myeloma. These parts of the study will find out whether these drugs are safe when used together.

View Study Details

Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Lead Researcher: Brea C Lipe

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidomide for 2 years and Lenalidomide + Daratumumab/rHuPH20. After 2 years of Maintenance, MRD is assessed to guide further therapy. MRD-positive patients will continue with the assigned treatment. MRD-negative patients will be further randomized (Reg Step 3) to either continue or discontinue the assigned treatment. Patients are treated for up to 7 years from Step 2 reg and followed for up to 15 years.

View Study Details

ULAB-16115 A program for following disease progression in Multiple Myeloma

Lead Researcher: Brea C Lipe

The purpose of this study is to collect clinical data along with bone marrow aspirate samples to see if there is a way to determine which patients are more or less likely to experience disease progression. This study will involve identifying different markers on the surfaces of the plasma cells and will look at protein expression. We will then correlate those findings with data from your medical records over time. If you decide to take part in this study, you will be asked to allow additional bone marrow aspirate and blood samples to be collected for research at several time points. These additional samples will be collected during routine testing time points as required for your routine care. We will also collect information about your disease and treatment from your medical record.

View Study Details

Publications

Journal Articles

8/4/2021
Keren DF, Bocsi G, Billman BL, Etzell J, Faix JD, Kumar S, Lipe B, McCudden C, Montgomery R, Murray DL, Rai AJ, Redondo TC, Souter L, Ventura CB, Ansari MQ. "Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies: Guideline From the College of American Pathologists in Collaboration With the American Association for Clinical Chemistry and the American Society for Clinical Pathology." Archives of pathology & laboratory medicine.. 2021 Aug 4; Epub 2021 Aug 04.

11/2020
Lipe, B. "Multiple Myeloma Insights: Older Adults With Multiple Myeloma: Q&A on Care Management" . Medpage Today. 2020; .

11/2020
Gasparetto, C; Lentzsch, S; Schiller, G; Callander, N; Tuchman, S; Chen, C; White, D; Kotb, R; Sutherland, H; Sebag, M; Baljevic, M; Bensinger, W; LeBlanc, R; Venner, C; Bahlis, N; Rossi, A; Biran, N; Sheehan, H; Saint-Martin, J; Van Domelen, D; Kai, K; Shah, J; Shacham, S; Kauffman, M; Lipe, B. "Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma" . eJHaem. 2020; .

VIEW ALL PUBLICATIONS

Close Window

Schedule an appointment with Brea C. Lipe, M.D.

Please answer the following questions to help us find the right appointment for you.

Important: If you believe that you have a medical or psychiatric emergency, please call 911 or go to the nearest hospital. This website is not intended for emergency care.

Have you seen this provider in the last 2 years?


Our policy does not permit patients to establish care with multiple providers within the same practice or specialty without prior approval. If you choose a new provider in the same office, we will cancel the appointment. Please contact the office directly with questions on this policy.